Radioactive cancer drug enters human testing
NCT ID NCT06925581
First seen Jan 04, 2026 · Last updated Apr 12, 2026 · Updated 18 times
Summary
This early-stage trial is testing a new radioactive drug called HRS-6768 in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find a safe and effective dose while checking how the drug moves through the body and delivers radiation to tumors. Researchers will enroll 84 patients to assess safety and see if the drug shows early signs of slowing cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gaobo Hospital
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.